Skip to search formSkip to main contentSkip to account menu

MK 0677

Known as: MK 677, MK-0677, MK-677 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
Context The age-related decline of growth hormone secretion may play a role in sarcopenia and frailty. Content In this randomized… 
Highly Cited
2005
Highly Cited
2005
Two nonpeptide (L692,429 and MK-677) and two peptide [GH-releasing peptide (GHRP)-6 and ghrelin] agonists were compared in… 
Highly Cited
2004
Highly Cited
2004
Objectives: To evaluate the effects of MK‐0677, an orally active growth hormone (GH) secretagogue, on functional recovery from… 
Highly Cited
1999
Highly Cited
1999
Highly Cited
1998
Highly Cited
1998
Obesity is associated with blunted GH secretion, unfavorable body composition, and increased cardiovascular mortality. The… 
Highly Cited
1998
Highly Cited
1998
The reversal of diet-induced negative nitrogen balance by GH suggests a possible therapeutic role for GH treatment in catabolic… 
1998
1998
The effect of 2 months of treatment with the oral growth hormone (GH) secretagogue MK‐677 on markers of bone metabolism was… 
Highly Cited
1996
Highly Cited
1996
Aging is associated with declining activity of the GH axis, possibly contributing to adverse body composition changes and… 
Highly Cited
1996
Highly Cited
1996
To assess the effects of prolonged administration of a novel analog of GH-releasing peptide (MK-677), nine healthy young men…